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Two groups have shown that, as in macaques in-
fected with simian immunodeficiency virus (SIV),
intestinal CD4
 
 
 
 T cells are selectively and rapidly
depleted in the intestine of HIV-infected patients.
Depletion of intestinal CD4
 
 
 
 T cells occurred at all
stages of infection regardless of highly active anti-
retroviral therapy (HAART). Here we discuss the
important implications of these papers for our un-
derstanding of HIV pathogenesis, treatment, and vac-
cine design.
 
It has been over 6 yr since we first described the rapid
and marked depletion of intestinal CD4
 
 
 
 T cells in SIV-
infected  macaques (1). We demonstrated that intestinal
CD4
 
 
 
 T cells were profoundly depleted in the lamina pro-
pria of the intestine of macaques within 14–21 d of SIV in-
fection, a time when the numbers of CD4
 
 
 
 T cells in the
blood or LNs (peripheral lymphoid tissues) were essentially
unchanged. Earlier studies had indicated that CD4
 
 
 
 T cells
were decreased in the intestine of HIV-infected patients in
chronic infection (2), but the major significance of the
macaque studies was the selectivity and speed of the deple-
tion. The fact that these cells were being eliminated within
days rather than months of infection challenged the prevail-
ing views that SIV and HIV were “slow” or “smoldering”
infections that did not induce immunodeficiency for several
months to years after infection. In fact, the differences were
so profound in the intestine within 14 d of SIV infection
that it suggested the viral replication kinetics were much
closer to those of other, more rapid viral infections rather
than a “lentiviral” infection (HIV and SIV are classified as
“lentiviruses,” which translates literally as “slow” viruses).
Subsequently, we showed that this depletion was selec-
tive for CD4
 
 
 
 T cells having an activated memory pheno-
type (3), a cell type which is abundant in the intestine but
rare in peripheral lymphoid tissues. Thus, we proposed that
only cells which were highly activated and thus transcribing
DNA could support high levels of replication sufficient for
“lytic” levels of viral replication. Conceivably, this alone
could explain the selective destruction of intestinal CD4
 
 
 
T cells. Intestinal lymphocytes and those in other mucosal
surfaces (such as lung, vagina) are frequently exposed to en-
vironmental antigens; thus, a much higher percentage of
mucosal lymphocytes are continually in a state of “activa-
tion.” However, the discovery of HIV coreceptors, and
soon afterwards the discovery that activated memory cells
selectively express CCR5, the major coreceptor for HIV
and SIV, provided an additional (yet complementary) ex-
planation for this selective CD4
 
 
 
 T cell depletion. Subse-
quently, we demonstrated that the intestinal CD4
 
 
 
 T cell
depletion was selective for CD4
 
 
 
 T cells co-expressing
CCR5, and this combined with the activated state of these
cells provided a likely explanation for the selective loss of
intestinal CD4
 
 
 
 T cells in early infection. We also demon-
strated that this rapid depletion occurs in all mucosal sites
examined, including the vagina and lung (4, 5). These find-
ings have now been verified in the intestine of HIV-infected
humans at virtually all stages of infection (6, 7). Although
this (once again) validates the SIV/macaque model of AIDS,
the major significance of these findings is that it supports a
simple hypothesis to explain much of the pathogenesis of
HIV infection—that most HIV replication occurs in the in-
testine and that disease progression may correlate with
turnover of specific cell subsets in mucosal tissues.
 
Changing Views of HIV Pathogenesis.
 
The findings pre-
sented in this issue, that the intestine is the earliest site of
CD4
 
 
 
 T cell depletion in HIV-infected patients and con-
firmation that this depletion occurs within the first few
weeks of exposure (the earliest that an infected patient was
examined; reference 6), perfectly parallel the macaque stud-
ies. Two papers in this issue (6, 7) demonstrate that effec-
tor memory (CCR5
 
 
 
) CD4
 
 
 
 T cells are rapidly eliminated
in HIV-infected patients, regardless of the stage of infec-
tion. If we extrapolate other findings from macaques, this
means that the major site of early viral replication in HIV-
infected patients is the intestine and other mucosal sites,
mainly because the vast majority of susceptible cells reside
in mucosal tissues.
The intestinal tract contains an abundance of both in-
ductive (Peyer’s patches, lymphoid follicles) and effector
(diffuse lamina propria) lymphoid tissues. Inductive sites
contain naïve, resting CD4
 
 
 
 (and CD8
 
 
 
) T cells which
rapidly migrate to effector lymphoid tissues upon exposure
to antigen (Fig. 1). Thus, most of the effector (CCR5
 
 
 
)
CD4
 
 
 
 T cells reside in these effector lymphoid tissues,
which are distributed throughout the length of the gas-
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trointestinal tract. Thus, in uninfected patients a vast pool
of these optimal viral target cells, i.e., those having a high
state of activation and co-expressing CD4 and CCR5, are
present in the intestine (8). Immediately after HIV expo-
sure, very high levels of viral replication occur in the intes-
tinal lamina propria, at least until these optimal target cells
are destroyed (which in macaques usually occurs by 14 d of
infection). Prior to this depletion, large numbers of SIV-
infected cells are detectable in the lamina propria, but once
these cells are eliminated most of the infected cells are lim-
ited to inductive lymphoid tissues (9), which is consistent
with observations made in humans by Mehandru et al. (6).
Subsequent infection of new cells and high levels of viral
replication is likely dependent on the rates of turnover of
Figure 1. Target cell distribution and viral replication in the intestinal tract. (A) In normal intestinal lymphoid tissue, naïve (CCR5 ) CD4  T cells
mostly reside in inductive sites (Peyer’s patches or organized lymphoid tissues; left), but these cells become activated and coexpress CCR5 as they are
exposed to the variety of antigens routinely encountered in the intestinal tract. After activation, CD4 CCR5  T cells rapidly recirculate and home to
effector sites (lamina propria) where they reside in large numbers (right). (B) During acute HIV infection, activated CCR5 CD4  T cells are rapidly elim-
inated from the lamina propria by HIV replication. This correlates with high levels of plasma viremia in primary infection, and loss of this subset may be a
major contributor to the post-peak decline in viremia. (C) In subacute/chronic HIV infection, substantial loss of CCR5 CD4  T cells in the lamina pro-
pria results in lower levels of virus in effector sites, but continual lymphocyte activation (from dietary antigens or intestinal microflora) in inductive sites
maintains viral replication within intestinal organized lymphoid tissues. In chronic infection, the majority of infected cells may be destroyed before reaching
effector sites, resulting in higher numbers of infected cells observed in organized lymphoid tissues. Intestinal lymphoid tissues with its inherent mechanisms
for lymphocyte activation and homing, thus serves as a reservoir for both viral persistence and ongoing replication. As a result, intestinal effector
CD4 CCR5  T cells are never restored in HIV-infected patients, even in patients receiving highly active antiretroviral therapy. 
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these cells in mucosal tissues. Examining intestinal tissues of
humans within 10 d of HIV infection is obviously difficult,
so primary infection studies continue to rely on SIV-infected
macaques. However, the data presented in this issue (6, 7)
strongly support a major role for mucosal tissues in the
pathogenesis of AIDS and suggest that HIV replication and
tissue distribution is largely dependent on the availability
and turnover of specific cells that are capable of being in-
fected (CD4
 
 
 
CCR5
 
 
 
) and producing virus (those that are
activated and transcribing DNA). Furthermore, the data
suggest that much of our understanding of the pathogenesis
of AIDS, which in turn influences vaccine design and ther-
apeutic strategies, has been biased by reliance on examina-
tion of peripheral blood. We would argue that studies ex-
amining peripheral blood alone provide a very limited and
in many cases misleading view of AIDS pathogenesis.
An understanding of the pathogenesis of HIV infection
has remained elusive. The fact that the majority of patients
are asymptomatic for months to years after infection, com-
bined with our inability to detect low levels of virus in
plasma, led some to propose concepts of viral “latency,” a
period in which the virus purportedly lay dormant, waiting
for some mysterious signal to begin replication and elimina-
tion of CD4
 
 
 
 T cells. These theories were largely debunked
by seminal studies by Ho et al. (10), who used antiretroviral
therapy to measure viral replication in HIV-infected patients.
This study demonstrated that active, high level replication
was ongoing in asymptomatic patients. However, it did not
indicate where this replication was occurring. Moreover,
since patients with CD4
 
 
 
 T cell depletion lacked sufficient
numbers of HIV-infected cells in the blood to account for
the CD4
 
 
 
 T cell depletion, others proposed “bystander
apoptosis” and/or “bone marrow suppression” to explain the
loss of CD4
 
 
 
 T cells. Apoptosis of uninfected CD4
 
 
 
 T cells
mediated by chronic immune stimulation was proposed to
explain the CD4
 
 
 
 T cell loss, but the findings in macaques,
confirmed in HIV-infected patients in the papers in this issue
(6, 7), both prove that there is nothing “chronic” about the
intestinal CD4
 
 
 
 T cell loss. In fact, the rapid nature of the
CD4
 
 
 
 T cell loss combined with the selective loss of acti-
vated CCR5
 
 
 
CD4
 
 
 
 T cells strongly supports the notion
that depletion is selective for HIV-infected cells, presumably
due to lytic levels of viral replication in cells that support it. It
is also likely that profound and sustained deficits in mucosal
immune responses are induced within days of HIV infection.
This is supported by the observation of asymptomatic oppor-
tunistic infections in SIV-infected macaques beginning as
early as 8 wk after infection (11).
Confirmation by Mehandru et al. (6) and Brenchley et
al. (7) that the intestine is the major site of viral replication
and CD4
 
 
 
 T cell depletion, essentially proves that examin-
ing events in the peripheral blood alone is inadequate for
detecting key events in the pathogenesis of HIV infection.
Moreover, these findings may provide a simplified explana-
tion for HIV replication and pathogenesis. HIV replication
may largely be governed by the presence and turnover of
viral “fuel cells,” i.e., those cells that have the appropriate
coreceptors for viral entry and the state of activation neces-
sary to produce lytic levels of virus. If these cells are turning
over in individual patients (either by enteritis, dietary aller-
gies, or even a heightened state of physiologic inflamma-
tion), viral replication is likely to increase (12). If these cells
are eliminated and the host does not make efforts to replen-
ish them, viral replication slows. Unfortunately, stimulation
of effector CD4
 
 
 
 T cells, which are necessary for immune
surveillance and “help” for essentially all other arms of the
immune system, is likely to exacerbate viral replication in
infected patients. This poses unique challenges to both vac-
cine design and HIV treatment strategies.
 
Implications for Treatment.
 
Recently, Anton et al. (13)
demonstrated that HIV could consistently be detected
in the intestine of HIV patients, even those receiving
HAART and with no detectable virus in plasma (13). Oth-
ers have demonstrated that higher frequencies of virus-spe-
cific CTL are present in the intestine of HIV-infected pa-
tients compared with blood (14). Both papers in this issue
(6, 7) demonstrate that mucosal effector CD4
 
 
 
 T cells are
not restored, even in patients receiving HAART. Com-
bined, these findings suggest that viral replication is ongo-
ing in the intestinal tract, regardless of HAART therapy.
The current trend in HIV therapy is to delay initiation of
HAART until patients are either symptomatic, have high
viremia, or demonstrate substantial CD4
 
 
 
 T cell loss in the
blood. In our experience, intestinal CD4
 
 
 
 T cells may be
at least partially restored in SIV-infected macaques receiv-
ing HAART, provided that treatment is initiated no later
that 1 wk after infection (unpublished data). Although it is
unlikely that such treatment regimens can be implemented
in humans, these data suggests that intestinal CD4
 
 
 
 T cells
are turning over and have the capacity to repopulate the in-
testine as long as this CD4
 
 
 
 T cell loss is stopped before the
restoration capacity of the thymus is depleted. There is
clearly an ongoing battle between HIV and the intestinal
immune system, regardless of viral loads in plasma, and it
seems logical that treatment should be initiated as soon as
possible to limit the continual destruction of intestinal CD4
 
 
 
T cells. Allowing continuous replication and CD4
 
 
 
 T cell
loss in the intestine undoubtedly results in the eventual loss
of important and irreplaceable CD4
 
 
 
 T cell clones and the
continual erosion of the immune system, despite being “all
quiet on the surface” (i.e., the peripheral blood).
Monitoring intestinal CD4
 
 
 
 T cells or viral loads in in-
testinal biopsies may also be useful for measuring responses
to therapy. Although current therapies seem inadequate for
clearing virus from the intestine, new therapeutic strategies
may benefit from monitoring intestinal CD4
 
 
 
 T cells and/
or viral loads in intestinal biopsies. Moreover, new thera-
pies aimed at blocking chemokine receptor–mediated fu-
sion may prove to be an effective adjunct therapy, particu-
larly in the mucosal immune system where the vast majority
of CD4
 
 
 
CCR5
 
 
 
 T cells reside.
 
Implications for Vaccines.
 
The fact that the intestine is the
earliest target for viral infection and CD4
 
 
 
 T cell loss
makes it clear that mucosal immunity will be essential for 
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designing an effective AIDS vaccine. It is increasingly ap-
parent that essentially all candidate vaccines that have
shown any promise have, in one way or another, induced
mucosal immune responses. Conversely, some candidate
vaccines that induced relatively strong systemic immune
responses have failed to provide adequate protection in
macaque models (for review see reference 15). It should
also be remembered that vaccines for other important dis-
eases with systemic manifestations were elusive until the
importance of the mucosal immune system was finally rec-
ognized. An effective vaccine for poliomyelitis, for exam-
ple, was elusive until a mucosal delivery system was imple-
mented, and this was considered previously to be a disease
of the central nervous system.
Given the confirmation herein, that HIV infection is pri-
marily a disease of the mucosal immune system (6, 7), it
should now be clear that candidate vaccines should be
tested for their ability to induce cell-mediated and antibody
responses specifically in mucosal tissues, or at least for their
ability to protect and preserve mucosal effector CD4
 
 
 
 T
cells. Although this is a daunting challenge in terms of the
design of clinical trials, it should also be appreciated that,
since the loss of intestinal CD4
 
 
 
 T cells occurs so rapidly,
evaluation or interpretation of at least this parameter alone
could be obtained in weeks, rather than months or years.
Thus, monitoring mucosal immune responses and/or pres-
ervation of intestinal CD4
 
 
 
 T cells could conceivably ac-
celerate evaluation of vaccine candidates, particularly in
nonhuman primate models. Regardless, the articles herein
(6, 7) should now make it clear the intestine is the “launch-
ing pad” for HIV infection, replication, and persistence,
and that stimulating mucosal immune responses will be key
in the development of an effective AIDS vaccine.
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